Zurich's Aeon passes $14M raised with seed extension for AI preventive health

What's the deal? Aeon, a Zurich-based provider of an AI-powered preventive health platform, has closed an undisclosed seed extension round. The raise, co-led by ArayaDealroom has a profile for this one. Try Dealroom → Ventures, brings the company's total funding to over $14 million.

Who else is in? Concentric, GoHub VenturesDealroom has a profile for this one. Try Dealroom →, Kadmos CapitalDealroom has a profile for this one. Try Dealroom →, Calm/Storm VenturesDealroom has a profile for this one. Try Dealroom →, N&V CapitalDealroom has a profile for this one. Try Dealroom →, and Bigwave Capital all participated.

What does it do? Aeon combines whole-body MRI, blood diagnostics covering over 100 biomarkers, and genetic risk analysis to deliver AI-driven risk prediction and personalised health check-ups. The platform integrates longitudinal multimodal data across imaging and blood testing to flag deviations early and predict individual health risks before disease occurs.

What's the money for? Aeon plans to integrate the technology and team of newly acquired Aware HealthDealroom has a profile for this one. Try Dealroom →, and to accelerate its European expansion roadmap.

Who's behind it? The company is led by founder and chief executive officer Tim Seithe.

The signal: Preventive healthcare startups are attracting investor interest as diagnostics shift from treating disease to predicting it. Aeon's bet is that combining imaging, blood work, and genetics under one AI model can catch risks earlier — and its acquisition of Aware Health suggests consolidation is already underway in the space.

Image credit: National Institutes of Health (NIH)